Elvitegravir cobicistat emtricitabine tenofovir adverse reactions

Elvitegravir cobicistat emtricitabine tenofovir
STRIBILD® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

ADVERSE Reactions

The following adverse drug reactions are discussed in other sections of the labeling:

• Lactic Acidosis/Severe Hepatomegaly with Steatosis [see Boxed Warning, Warnings and Precautions].
• Severe Acute Exacerbations of Hepatitis B [see Boxed Warning, Warnings and Precautions].
• New Onset or Worsening Renal Impairment [see Warnings and Precautions ].
• Bone Effects of Tenofovir DF [see Warnings and Precautions ].
• Immune Reconstitution Syndrome [see Warnings and Precautions].

References

Adapted from the FDA Package Insert.